Board Certified Cardiology Pharmacist (BCCP) Practice Exam

In the scenario of pulseless ventricular tachycardia (VT), the most appropriate immediate action is to perform biphasic defibrillation. Pulseless VT is a life-threatening rhythm that requires rapid intervention to restore effective cardiac function. Defibrillation is crucial because it delivers an electrical shock to the heart, which can help restore a normal rhythm by interrupting the chaotic electrical activity causing the pulseless state.

The immediate goal is to convert the arrhythmia and restore perfusion. Biphasic defibrillation has been shown to be more effective than monophasic in terminating VT and has lower energy requirements for successful cardioversion. The initial shock dose typically recommended in advanced cardiac life support (ACLS) guidelines is 200 joules when using a biphasic defibrillator.

While other medications like magnesium sulfate, amiodarone, and lidocaine may be helpful in certain cases of arrhythmias, they are not first-line treatments for pulseless VT that is not responsive to CPR. Administering these medications is appropriate after defibrillation attempts if the patient remains in a rhythm that is not responsive to shocks or if rhythms such as stable monomorphic VT are present. However, in an emergency situation with